Log in

NYSE:HAEHaemonetics Stock Price, Forecast & News

$108.14
+1.69 (+1.59 %)
(As of 05/25/2020 03:31 PM ET)
Add
Compare
Today's Range
$106.12
Now: $108.14
$109.04
50-Day Range
$91.62
MA: $104.96
$116.74
52-Week Range
$63.41
Now: $108.14
$140.36
Volume450,591 shs
Average Volume432,021 shs
Market Capitalization$5.44 billion
P/E Ratio73.56
Dividend YieldN/A
Beta0.74
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Read More
Haemonetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.78 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$988.48 million
Cash Flow$5.60 per share
Book Value$11.67 per share

Profitability

Net Income$76.53 million

Miscellaneous

Employees3,004
Market Cap$5.44 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Haemonetics (NYSE:HAE) Frequently Asked Questions

How has Haemonetics' stock been impacted by COVID-19 (Coronavirus)?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HAE shares have increased by 4.3% and is now trading at $108.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Haemonetics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Haemonetics.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Haemonetics.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings data on Tuesday, May, 5th. The medical instruments supplier reported $0.69 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.73 by $0.04. The medical instruments supplier earned $238.50 million during the quarter, compared to analyst estimates of $246.53 million. Haemonetics had a return on equity of 29.33% and a net margin of 7.74%. The company's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 earnings per share. View Haemonetics' earnings history.

What price target have analysts set for HAE?

7 brokers have issued 12 month price objectives for Haemonetics' shares. Their forecasts range from $125.00 to $145.00. On average, they expect Haemonetics' share price to reach $136.83 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price. View analysts' price targets for Haemonetics.

Has Haemonetics been receiving favorable news coverage?

Media coverage about HAE stock has been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Haemonetics earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutHaemonetics.

Are investors shorting Haemonetics?

Haemonetics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,350,000 shares, a decrease of 24.2% from the April 30th total of 1,780,000 shares. Based on an average daily volume of 554,400 shares, the days-to-cover ratio is presently 2.4 days. Currently, 2.7% of the company's stock are sold short. View Haemonetics' Current Options Chain.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Align Technology (ALGN), Netflix (NFLX), NVIDIA (NVDA), Citigroup (C), Johnson & Johnson (JNJ), Micron Technology (MU) and Pfizer (PFE).

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher Simon, CEO, Pres & Director (Age 55)
  • Mr. William P. Burke, CFO & Exec. VP
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
  • Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.88%), Capital Research Global Investors (5.75%), Wellington Management Group LLP (4.48%), State Street Corp (3.33%), Franklin Resources Inc. (2.03%) and Eminence Capital LP (1.68%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View institutional ownership trends for Haemonetics.

Which major investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Morgan Stanley, Two Sigma Investments LP, JPMorgan Chase & Co., AQR Capital Management LLC, UBS Group AG, Russell Investments Group Ltd., and Federated Hermes Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh, and William P Mr Burke. View insider buying and selling activity for Haemonetics.

Which major investors are buying Haemonetics stock?

HAE stock was purchased by a variety of institutional investors in the last quarter, including Eminence Capital LP, Waddell & Reed Financial Inc., KAMES CAPITAL plc, Eaton Vance Management, Capital World Investors, Capital Research Global Investors, Nuveen Asset Management LLC, and SG Americas Securities LLC. View insider buying and selling activity for Haemonetics.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $108.14.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $5.44 billion and generates $988.48 million in revenue each year. The medical instruments supplier earns $76.53 million in net income (profit) each year or $3.31 on an earnings per share basis. Haemonetics employs 3,004 workers across the globe.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.